Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "API"

3333 News Found

Lundbeck’s bocunebart shows breakthrough potential in migraine prevention
Clinical Trials | February 16, 2026

Lundbeck’s bocunebart shows breakthrough potential in migraine prevention

Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide


BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
Biopharma | February 16, 2026

BridgeBio reports breakthrough results in Phase 3 achondroplasia trial

Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone


BioAsia 2026 positions Telangana as a global TechBio powerhouse
News | February 14, 2026

BioAsia 2026 positions Telangana as a global TechBio powerhouse

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem


Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
News | February 14, 2026

Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods

Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore


Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal
Supply Chain | February 14, 2026

Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal

Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories


Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial
Clinical Trials | February 14, 2026

Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial

PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients


IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
News | February 13, 2026

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY


Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
News | February 13, 2026

Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer

KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components


Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
News | February 13, 2026

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore